CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Gangneung, Korea, Republic of

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)

    This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy.

    Phase

    3

    Span

    288 weeks

    Sponsor

    Revolution Medicines, Inc.

    San Juan

    Recruiting

  • Oral Metformin for Treating Melasma in Latin American Women

    Phase

    1/2

    Span

    15 weeks

    Sponsor

    University of Puerto Rico

    San Juan

    Recruiting

  • A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

    Study details include: The study duration will be up to 63 days (9 weeks). - 1 or 2 screening visits (up to 28 days before treatment) - 28 days of treatment including 5 clinic visits - Week 1: 24-hour in-clinic stay (Day 1) - Week 2: Outpatient clinic visit (Day 7) - Week 3: Outpatient clinic visit (Day 14) - Week 4: Telephone visit (Day 21) - Week 5: 24 to 48-hour in-clinic stay (Day 28) - Week 6: Follow-up visit (Day 35) Disclosure Statement: The study consists of two cohorts, each with a parallel-group design and two arms, with participants blinded to treatment allocation. Number of Participants: The study will randomise approximately 36 participants in total. Cohort A: Approximately 75 participants with presumed MASH/NASH with fibrosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo. Cohort B: Approximately 75 participants with SLD with advanced fibrosis including compensated cirrhosis will be screened such that approximately 18 participants will be randomised. Twelve participants will be randomised to receive AZD2389 and 6 participants will receive placebo

    Phase

    2

    Span

    53 weeks

    Sponsor

    AstraZeneca

    San Juan

    Recruiting

  • A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

    Phase

    1

    Span

    77 weeks

    Sponsor

    Hoffmann-La Roche

    San Juan

    Recruiting

  • A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)

    Phase

    2

    Span

    128 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    San Juan

    Recruiting

  • A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

    Phase

    3

    Span

    122 weeks

    Sponsor

    GlaxoSmithKline

    San Juan

    Recruiting

    Healthy Volunteers

  • A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    Phase

    3

    Span

    374 weeks

    Sponsor

    Merck Sharp & Dohme LLC

    San Juan

    Recruiting

  • Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

    Phase

    N/A

    Span

    106 weeks

    Sponsor

    Vertex Pharmaceuticals Incorporated

    San Juan

    Recruiting

  • A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).

    Phase

    3

    Span

    255 weeks

    Sponsor

    AstraZeneca

    San Juan

    Recruiting

  • A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

    Phase

    2

    Span

    136 weeks

    Sponsor

    Vaxcyte, Inc.

    San Juan

    Recruiting

    Healthy Volunteers

1-10 of 260
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information